Researchers at Yale have found that a lupus-related autoantibody sensitizes cancer cells to DNA-damaging radiation and chemotherapy. The antibody, which has already proven safe in a clinical trial in SLE, may be effective as a monotherapy for patients with BRCA-mutant cancers.